CoChat
Sign Up
PreprintCited by 511RNA and protein synthesis mechanismsSARS-CoV-2 and COVID-19 ResearchRNA Interference and Gene Delivery

Algorithm for Optimized mRNA Design Improves Stability and Immunogenicity

Open access
Zhang, He, Zhang, Liang, Lin, Ang, Xu, Congcong, Li, Ziyu, Liu, Kaibo, Liu, Boxiang, Ma, Xiaopin +6 more·2020·arXiv
DOI 10.48550/arxiv.2004.10177arXiv 2004.10177PMC PMC10499610
Open this paper in CoChat — free accountOpen PDF

Abstract

Messenger RNA (mRNA) vaccines are being used for COVID-19, but still suffer from the critical issue of mRNA instability and degradation, which is a major obstacle in the storage, distribution, and efficacy of the vaccine. Previous work showed that optimizing secondary structure stability lengthens mRNA half-life, which, together with optimal codons, increases protein expression. Therefore, a principled mRNA design algorithm must optimize both structural stability and codon usage to improve mRNA efficiency. However, due to synonymous codons, the mRNA design space is prohibitively large, e.g., there are $\sim\!10^{632}$ mRNAs for the SARS-CoV-2 Spike protein, which poses insurmountable challenges to previous methods. Here we provide a surprisingly simple solution to this hard problem by reducing it to a classical problem in computational linguistics, where finding the optimal mRNA is akin to finding the most likely sentence among similar sounding alternatives. Our algorithm, named LinearDesign, takes only 11 minutes for the Spike protein, and can jointly optimize stability and codon usage. Experimentally, without chemical modification, our designs substantially improve mRNA half-life and protein expression in vitro, and dramatically increase antibody response by up to 23$\times$ in vivo, compared to the codon-optimized benchmark. Our work enables the exploration of highly stable and efficient designs that are previously unreachable and is a timely tool not only for vaccines but also for mRNA medicine encoding all therapeutic proteins (e.g., monoclonal antibodies and anti-cancer drugs).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

DataCite · 10.48550/arxiv.2004.10177

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 33

  1. Mauger DM, et al. (2019) mRNA structure regulates protein expression through changes in functional half-life. Proceedings of the National Academy of Sciences U.S.A. 116(48):24075-24083.
  2. Hall KB (2005) Best-first Word-lattice Parsing: Techniques for integrated syntactic language modeling. PhD Thesis, Brown University.
  3. Schlake T, et al. (2019) mRNA: a novel avenue to antibody therapy? Molecular Therapy 27(4):773-784.
  4. Reinhard K, et al. (2020) An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 367(6476):446-453.
  5. Wolff JA, et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247(4949):1465-1468.
  6. Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines-a new era in vaccinology. Nature Reviews Drug Discovery 17(4):261-279.
  7. Mauro VP, Chappell SA (2014) A critical analysis of codon optimization in human therapeutics. Trends in molecular medicine 20(11):604-13.
  8. Gustafsson C, Govindarajan S, Minshull J (2004) Codon bias and heterologous protein expression. Trends in Biotechnology 22(7):346-353.
  9. Nabiyouni M, Prakash A, Fedorov A (2013) Vertebrate codon bias indicates a highly GC-rich ancestral genome. Gene 519(1):113-119.
  10. Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics-developing a new class of drugs. Nature reviews Drug discovery 13(10):759-780.
  11. Mathews DH, Sabina J, Zuker M, Turner DH (1999) Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. Journal of Molecular Biology 288(5):911-940.
  12. Mathews DH, et al. (2004) Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proceedings of the National Academy of Sciences U.S.A. 101(19):7287-7292.
  13. Sharp PM, Li WH (1987) The codon adaptation index-a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Research 15(3):1281-1295.
  14. Durbin R, Eddy SR, Krogh A, Mitchison G (1998) Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids. (Cambridge University Press, Cambridge, UK).
  15. Bar-Hillel Y, Perles M, Shamir E (1961) On formal properties of simple phrase structure grammars. Zeitschrift für Phonetik, Sprachwissenschaft und Kommunikationsforschung 14(2):143-172.
  16. Nederhof MJ, Satta G (2003) Probabilistic Parsing as Intersection. Proceedings of the Eighth International Conference on Parsing Technologies pp. 137-148.
  17. Huang L, et al. (2019) LinearFold: linear-time approximate RNA folding by 5'-to-3' dynamic programming and beam search. Bioinformatics 35(14): i295-i304.
  18. Cohen B, Skiena S (2003) Natural selection and algorithmic design of mRNA. Journal of Computational Biology 10(3-4):419-432.
  19. Terai G, Kamegai S, Asai K (2016) CDSfold: an algorithm for designing a protein-coding sequence with the most stable secondary structure. Bioinformatics 32(6):828-834.
  20. Huang L, Sagae K (2010) Dynamic programming for linear-time incremental parsing. Proceedings of the 48th Annual Meeting of the Association for Computational Linguistics pp. 1077-1086.
  21. Yang R, et al. (2021) A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal transduction and targeted therapy 6(1):1-10.
  22. Liu L, et al. (2008) Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320(5874):379-381.
  23. Mignone F, Gissi C, Liuni S, Pesole G (2002) Untranslated regions of mRNAs. Genome biology 3(3):1-10.
  24. Leppek K, et al. (2022) Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nature communications 13(1):1-22.
  25. Rana MM (2021) Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. Journal of Biomaterials Science, Polymer Edition 32(9):1219-1249.
  26. Wrapp D, et al. (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367(6483):1260-1263.
  27. Cunningham AL, et al. (2016) Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine 375(11):1019-1032.
  28. Raab D, Graf M, Notka F, Schödl T, Wagner R (2010) The GeneOptimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Systems and Synthetic Biology 4(3):215-225.
  29. Wayment-Steele HK, et al. (2021) Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic acids research 49(18):10604-10617.
  30. Hie B, Zhong ED, Berger B, Bryson B (2021) Learning the language of viral evolution and escape. Science 371(6526):284-288.
  31. Madani A, et al. (2023) Large language models generate functional protein sequences across diverse families. Nature Biotechnology pp. 1-8.
  32. Karikó K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23(2):165-175.
  33. Karikó K, et al. (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular therapy 16(11):1833-1840.

Cited by

Sorted by citations

Authors
Zhang, H., Zhang, L., Lin, A., Xu, C., Li, Z., Liu, K., Liu, B., Ma, X., Zhao, F., Yao, W., Li, H., Mathews, D. H., Zhang, Y., & Huang, L.
Affiliations
  • Oregon State University (US)
  • China Pharmaceutical University (CN)
  • Baidu (China) (CN)
  • National University of Singapore (SG)
  • University of Rochester Medicine (US)
Corresponding author
  • Zhang, Liang
  • Li, Hangwen
  • Mathews, David H.
  • Zhang, Yujian
  • Huang, Liang
ORCID
Venue
arXiv
Publisher
arXiv
Published
2020
Volume
621
Issue
7978
Pages
396-403
ISSN
0028-0836 (ISSN-L)
DOI
10.48550/arxiv.2004.10177
arXiv
2004.10177
PMC
PMC10499610
OpenAlex
W4367681391
Cited by
511
References
0
Citations by year
2026: 182 · 2025: 177 · 2024: 117 · 2023: 30 · 2022: 3 · 2021: 1 · 2020: 1
FWCI
43.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • arXiv (Cornell University) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • arXiv (Cornell University)
Funders
  • Pfizer
  • Sanofi
  • Baidu
  • National Institutes of Health
  • University of California, Davis
  • National Institute of General Medical Sciences (R35GM145283)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
mRNA vaccine design, mRNA stability, codon optimization, SARS-CoV-2 spike protein, mRNA secondary structure, immunogenicity, antibody titers, mRNA half-life, varicella-zoster vaccine, mRNA therapeutics
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Algorithms, Animals, Codon, Half-Life, Humans, RNA, Messenger, Herpesvirus 3, Human, RNA Stability, Mice, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review